

# NURITAS

Life-changing Discoveries

Discovery on Demand

# Corporate Overview

- Nuritas deploy multiple technologies to revolutionise and accelerate drug discovery in areas defined by our collaborating partners
  - Convergence of computational approaches with wet sciences ('omics) rapidly and efficiently predict patentable peptides with desired characteristics
  - Starting with natural & safe sources, our AI identifies inherently low toxicity drug backbones for further synthetic development
  - Globally our data is unique & proprietary – yielding insights like no others
  - Our approach has been proven & validated by global leaders
- Privately held, founded in 2014
  - Backing from
    - ❖ New Protein Capital
    - ❖ Ali Partovi (Facebook & Dropbox)
    - ❖ U2's Bono and The Edge
    - ❖ Salesforce CEO Marc Benioff



**Nestlé** **BASF**


# The Peptide Revolution- Why Now?

- Urgent need to push boundaries of traditional drug design & discover innovative molecules to modulate/cure disease
- Peptides, as natural intrinsic signalling molecules, hold such promise
- Natural safe sources of peptides, co evolved with man, offer reservoir of new low toxicity drug candidates (safer/green/sustainable)
- Technology advances can now mine billions of once hidden actives for desired characteristics
- Prior liabilities now less problematic due to advances in synthetic chemistry, formulation (pharmacokinetics,  $T_{1/2}$ , stability, solubility)


## The Promise of Peptides beyond “Traditional” Peptide Therapies

- Unique properties- molecularly poised between small molecules & biologics - new promise as candidates against “undruggable”, intracellular targets
- New peptides in clinic already extending beyond traditional treatment modalities
  - ✓ protein-protein interactions,
  - ✓ target receptor tyrosine kinases
  - ✓ inhibit intracellular target

Compact Binding: Small Molecule Inhibitor



Extended Binding via Peptide



- Using AI as the compass- Nuritas locate, target and unlock desired and specific actives from:
  - selected sources (natural parent)
  - for synthetic strategies (synthetic homologue)
  - to improve characteristics (modification/optimisation strategies)
- Each step is guided/accelerated via technology and validated via traditional experimental laboratory methodologies (fully integrated approach)
- Nuritas proprietary platforms (Nπφ™) draw from multiple technology stacks and AI approaches to
  - Define disease area (Target)
  - Predict new theoretical drugs (Predict)
  - Specifically unlock from source via AI informed proprietary process (Unlock)
  - Optimisation/modification strategies for improved properties (enabled by In Silico design)
- Using data **proprietary** to Nuritas, our AI can analyse billions of molecules and peptides to predict and identify how they impact specific health areas and disease aspects.



# Nuritas Industry Focus & Discovery Models

**Dermatology, Consumer**



**Pharmaceuticals**




**Discovery On Demand**



**Industry Focus**

A green apple is the central focus, with a white outline of a hexagon containing the word 'PREDICT' and a 'TARGET UNLOCK' icon below it. The background is a dark blue with faint binary code.

**Models**

A green apple is the central focus, with a white outline of a hexagon containing the word 'PREDICT' and a 'TARGET UNLOCK' icon below it. The background is a dark blue with faint binary code.

**Smart Agriculture**



**Functional Ingredients**




**Already Discovered Pipeline**

# Discovery on Demand

## Flexible and Adaptable

Nuritas On Demand Responds to Industry Needs  
Our AI Platforms are flexible and adaptable to multiple disease areas and industry defined discovery challenges



Bubble Size: Large: existing in house discovery programs, Small: emerging in house discovery programs

## Fully Integrated- End to End Discovery

Engage across the entire spectrum : in silico discovery-pre clinical validation

**Benefits:** Progression of “best chance” candidates to clinic (cost, time, clinical relevance)

## Improve Success of Existing In House Programs with new candidates

Or

**Provide new discovery pipelines for new discovery strategies/diseases**

1

## Natural Parent Peptide

- Starting blocks of low inherent toxicity (improved basal tox/safety)
- Synthetic modifications improve characteristics

2

Potential to test natural parent **in humans** under food regulated “clinical trails”: cost & candidate selection pre Pharma Clinical Trials

3

## Cost Effective Innovation

Platform can identify peptides ten times faster and 500 times more accurately (cost, time, efficacy benefit)

4

## High Speed & Evolving Predictions

Machine learning permits AI evolution for greater predictive ability

5

## Novel Product Differentiation

Every bioactive peptide Nuritas discovers is novel and patentable

6

## Proven Model


Proven validated model with industry partners

First Nuritas AI discovered ingredient to be commercialised by partner by year end

## Current Disease Areas



## Future Areas of Interest (via Industry Collaborations)



## Future Discovery Strategies (via Industry Collaborations)



## AI Benefit



✓ **Complicated Diseases**

✓ **Complicated Data**

## Collaboration

Collaboration both parties leverage competencies and strengths to discover-develop drugs

## Deal Milestones

Payments staggered and based on the success of development milestones



## Upfront Payments

Upfront payment adjusted to provide a trade-off mechanism for royalties using a net present value calculation

## Royalties

Royalty percentages can be negotiated to reflect the value and probability of success of the drug candidates

To find out more about our  
Discovery on Demand service,  
please contact

**Chantelle Kiernan**  
**Director Lifesciences**

Nuritas  
Kiernan.Chantelle@Nuritas.com

**Headquarters and Lab**

Dublin, Ireland

Tel: +353-(0)1-430-1290

Mob: +353 (87)- 760-0815

[www.nuritas.com](http://www.nuritas.com)

[twitter.com/NuritasResearch](https://twitter.com/NuritasResearch)

